• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Heron Therapeutics Inc.

    5/6/25 5:00:45 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRTX alert in real time by email
    S-8 1 hrtx-20250506.htm S-8 S-8

    As filed with the Securities and Exchange Commission on May 6, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

    Heron Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

    94-2875566

    (State or other jurisdiction of incorporation or organization)

    (I.R.S. Employer Identification No.)

    100 Regency Forest Drive, Suite 300, Cary, NC

    (Address of Principal Executive Offices)

     

     

     

    27518

    (Zip Code)

     

    Non-Plan Inducement Stock Option Grant

    Non-Plan Inducement Performance-Vesting Stock Option Grant

    Non-Plan Inducement Restricted Stock Unit Grant

    (Full Title of the Plans)

    Ira Duarte

    Executive Vice President, Chief Financial Officer

    Heron Therapeutics, Inc.

    100 Regency Forest Drive, Suite 300

    Cary, North Carolina 27518

    (Name and address of agent for service)

    (858) 251-4400

    (Telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☒

     

     

     

     

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

     

     

     

     

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed to register 1,900,000 shares of common stock, par value $0.01 per share (“Common Stock”), of Heron Therapeutics, Inc. (the “Registrant”), consisting of:

    •
    an aggregate of 1,400,000 shares of Common Stock issuable upon the exercise of outstanding stock options granted to Mark Hensley, the Registrant’s Chief Operating Officer (“Hensley”), outside of a plan as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Options”); and
    •
    500,000 shares of Common Stock issuable upon the vesting of restricted stock units granted to Hensley, outside of a plan as an inducement equity award in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement RSUs” and, together with the Inducement Options, the “Inducement Awards”).

    The Inducement Awards were approved by the Compensation Committee of the Registrant’s Board of Directors as an inducement material to Hensley entering into employment with the Registrant.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The documents containing the information required in Part I of this Registration Statement have been or will be sent or given to the participating employee as specified in Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”), in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “Commission”). Such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act of 1933, as amended (the “Securities Act”). These documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents have been filed by the Registrant with the Commission and are incorporated herein by reference:

    •
    the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Commission on February 27, 2025;
    •
    the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 filed with the Commission on May 6, 2025;
    •
    the Registrant’s Current Reports on Form 8-K filed with the Commission on February 20, 2025 and April 29, 2025;
    •
    the portions of the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 30, 2025 that are specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024; and

    2

     

     


    •
    The description of the Registrant’s Common Stock contained in Exhibit 4.4 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Commission on February, 27, 2025, including any amendments or reports filed for the purpose of updating such description.

    All reports and other documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof, and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents. The Registrant is not incorporating by reference any reports or documents or portions thereof that are not considered to be “filed” with the Commission.

    Any statement contained herein or in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated herein by reference modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities

    Not applicable.

    Item 5. Interests of Named Experts and Counsel

    Not applicable.

    Item 6. Indemnification of Directors and Officers

    The Registrant is incorporated under the laws of the State of Delaware. Section 102 of the Delaware General Corporation Law (the “DGCL”) permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.

    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

    As permitted by the DGCL, Section B of Article VI of the Registrant’s Certificate of Incorporation provides:

    (1) Right to Indemnification. Each person who was or is made a party or is threatened to be made a party to or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a “proceeding”), by reason of the fact that he or she, or a person of whom he or she is the legal representative, is or was a director or officer, of the Corporation or is or was serving at the request of the

    3

     

     


    Corporation, as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent, shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the General Corporation Law of the State of Delaware, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide prior to such amendment), against all expense, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such person in connection therewith and such indemnification shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of his or her heirs, executors and administrators; provided, however, that, the Corporation shall indemnify any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the board of directors of the Corporation. The right to indemnification conferred in this Section B shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending any such proceeding in advance of its final disposition; provided, however, that, if the General Corporation Law of the State of Delaware requires, the payment of such expenses incurred by a director or officer in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such person while a director or officer, including, without limitation, service to an employee benefit plan) in advance of the final disposition of a proceeding, shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified under this Section or otherwise. The Corporation may, by action of its board of Directors, provide indemnification to employees and agents of the Corporation with the same scope and effect as the foregoing indemnification of directors and officers.

    (2) Non-Exclusivity of Rights. The right to indemnification and the payment of expenses incurred in defending a proceeding in advance of its final disposition conferred in this Section B shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, provision of this Certificate of Incorporation, Bylaw, agreement, vote of stockholders or disinterested directors or otherwise.

    (3) Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any such expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law.

    In addition, the Registrant has entered into agreements with its directors and executive officers that require it to indemnify them against expenses including, among other things, attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding, whether actual or threatened, to which such person may be made a party by reason of the fact that such person is or was a director or officer of the Registrant, provided such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the best interests of the Registrant. The indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder. At present, no litigation or proceeding is pending that involves any of the Registrant’s directors or officers regarding which indemnification is sought, nor is the Registrant aware of any threatened litigation that may result in claims for indemnification.

    Item 7. Exemption From Registration Claimed

    Not applicable.

    4

     

     


    Item 8. Exhibits

     

     

     

    Exhibit No.

    Description

     

     

        4.1

    Certificate of Incorporation, as amended through July 29, 2009 (incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, as Exhibit 3.1, filed on August 4, 2009)

     

     

        4.2

    Certificate of Amendment of Certificate of Incorporation (incorporated by reference to the Registrant’s Current Report on Form 8-K, as Exhibit 3.1, filed on June 30, 2011)

     

     

        4.3

    Certificate of Amendment to the Certificate of Incorporation (incorporated by reference to the Registrant’s Current Report on Form 8-K, as Exhibit 3.1, filed on January 13, 2014)

     

     

        4.4

    Certificate of Amendment to the Certificate of Incorporation (incorporated by reference to the Registrant’s Post-Effective Amendment to its Registration Statement on Form 8-A/A, filed on July 6, 2017)

     

     

        4.5

    Certificate of Amendment to the Certificate of Incorporation (incorporated by reference to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2018, as Exhibit 3.6, filed on February 22, 2019)

     

     

        4.6

    Certificate of Amendment to the Certificate of Incorporation (incorporated by reference to the Registrant’s Current Report on Form 8-K, as Exhibit 3.1, filed on June 12, 2023)

     

     

        4.7

    Certificate of Amendment to the Certificate of Incorporation (incorporated by reference to the Registrant’s Current Report on Form 8-K, as Exhibit 3.1, filed on June 18, 2024)

     

     

     

        4.8

     

    Amended and Restated Bylaws (incorporated by reference to the Registrant’s Current Report on Form 8-K, as Exhibit 3.1, filed on February 8, 2019)

     

     

        5.1

    Opinion of K&L Gates LLP*

     

     

      23.1

    Consent of K&L Gates LLP (included in Exhibit 5.1 above)*

     

     

      23.2

    Consent of WithumSmith+Brown, PC, independent registered public accounting firm*

     

     

      24.1

    Power of Attorney (included on the signature page)*

     

     

      99.1

    Form of Inducement Notice of Grant of Stock Options and Option Agreement*

     

     

      99.2

    Form of Inducement Notice of Grant of Restricted Stock Units and Restricted Stock Unit Agreement*

     

     

      99.3

     

    Form of Inducement Notice of Grant of Performance-Vesting Non-Statutory Stock Options and Performance-Vesting Non-Statutory Stock Option Agreement*

     

     

    107.1

    Filing Fee Table*

     

    *

    Filed herewith.

     

    Item 9. Undertakings.

    1. The undersigned registrant hereby undertakes:

    (a) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range

    5

     

     


    may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fees” table in the effective Registration Statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    (b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    2. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    6

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cary, State of North Carolina, on May 6, 2025.

     

     

     

    HERON THERAPEUTICS, INC.

    (Registrant)

     

     

    By:

    /s/ Ira Duarte

     

    Ira Duarte

    Executive Vice President, Chief Financial Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Craig Collard and Ira Duarte, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    7

     

     


     

     

     

     

     

    Signature

    Title

    Date

     

     

     

    /s/ Craig Collard

    Craig Collard

    Chief Executive Officer and Director

    (Principal Executive Officer)

    May 6, 2025

     

     

     

    /s/ Ira Duarte

    Ira Duarte

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    May 6, 2025

     

     

     

     

    /s/ Adam Morgan

    Adam Morgan

    Chairman of the Board of Directors

    May 6, 2025

     

     

     

     

    /s/ Sharmila Dissanaike

    Sharmila Dissanaike

    Director

    May 6, 2025

     

     

     

     

    /s/ Craig Johnson

    Craig Johnson

    Director

    May 6, 2025

     

     

     

     

    /s/ Michael Kaesta

     

    Director

     

    May 6, 2025

    Michael Kaseta

     

     

     

     

     

    /s/ Susan Rodriguez

    Susan Rodriguez

    Director

    May 6, 2025

     

     

     

     

    /s/ Christian Waage

    Christian Waage

    Director

    May 6, 2025

     

     

    8

     

     


    Get the next $HRTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HRTX

    DatePrice TargetRatingAnalyst
    6/9/2025$6.00Buy
    H.C. Wainwright
    6/13/2024$7.00Buy
    Rodman & Renshaw
    4/23/2024$6.00Overweight
    CapitalOne
    3/13/2024$4.00 → $5.00Buy
    Needham
    More analyst ratings

    $HRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

    CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. "We are encouraged by the growth in Q4 2025, driven in particular by the momentum in our Acute Care franchise with ZYNRELEF® and APONVIE®," said Craig Collard, Chief Executive Officer of Heron. "In addition to our revenue growth, we are extremely pleased with the continued progress made across all aspects of our business throughout the past year." Preliminary Fourth Quarter and Full Year 2025 Updates Net revenue of approximately $40.5 million for the

    1/9/26 9:29:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

    APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 ("NK-1") antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker onset than oral aprepitantAprepitant alone, or added to a multimodal regimen, recognized as significantly reducing the risk of PONV, and aprepitant monotherapies are noted as more effective compared to 5-HT3 receptor antagonists for postoperative vomiting preventionPost-discharge nausea and vomiting (PDNV) recognized as a significant risk to discharged postoperative patients and the role of long-acting antiemetic strategies highlighted as extending protection beyond the recovery room and into the

    12/4/25 8:15:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

    Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 millionZYNRELEF® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the launch of the Vial Access Needle (VAN) and enhanced incentive program with key distributorsAPONVIE® Net Revenue grew 173% in Q3 2025, as compared to Q3 2024, supported by increased adoption and momentum building with the newly launched dedicated sales team in Q3 2025 CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage

    11/4/25 8:00:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

    11/22/24 4:36:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for APONVIE issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling

    3/11/24 4:38:31 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CINVANTI issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling

    3/11/24 4:38:29 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cusack Thomas was granted 53,960 shares (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    2/3/26 10:00:07 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Financial Officer Duarte Ira

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    2/3/26 10:00:10 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Johnson Craig A was granted 53,960 shares (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    2/3/26 10:00:08 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Rubric Capital Management Lp bought $3,580,838 worth of shares (2,387,225 units at $1.50) (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    8/12/25 6:00:17 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Morgan Adam bought $2,649,819 worth of shares (1,766,546 units at $1.50) (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    8/12/25 5:02:36 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forbes William P bought $27,250 worth of shares (25,000 units at $1.09), increasing direct ownership by 46% to 79,000 units (SEC Form 4)

    4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

    11/21/23 12:19:26 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Heron Therapeutics Inc.

    SCHEDULE 13G - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

    1/30/26 2:20:00 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)

    1/9/26 1:08:24 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Heron Therapeutics Inc.

    SCHEDULE 13G - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

    11/26/25 10:15:35 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Heron Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $6.00

    6/9/25 7:51:39 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Heron Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $7.00

    6/13/24 7:14:56 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CapitalOne initiated coverage on Heron Therapeutics with a new price target

    CapitalOne initiated coverage of Heron Therapeutics with a rating of Overweight and set a new price target of $6.00

    4/23/24 6:55:56 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

    CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025.  Mr. Cusack has more than 20 years of experience in investment management and corporate finance. 

    10/29/25 5:58:14 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

    CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. "I am excited to welcome Mark to Heron as our new Chief Operating Officer," said Craig Collard, Chief Executive Officer of Heron. "Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficienc

    4/28/25 6:55:00 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

    SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Mr. Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Thera

    11/4/24 5:00:00 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    Financials

    Live finance-specific insights

    View All

    Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

    Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 millionZYNRELEF® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the launch of the Vial Access Needle (VAN) and enhanced incentive program with key distributorsAPONVIE® Net Revenue grew 173% in Q3 2025, as compared to Q3 2024, supported by increased adoption and momentum building with the newly launched dedicated sales team in Q3 2025 CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage

    11/4/25 8:00:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

    CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to report third quarter 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under

    10/21/25 4:20:00 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress

    Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 millionDelivered record year-to-date 2025 Adjusted EBITDA of $7.9 million, raised full-year 2025 Adjusted EBITDA Guidance from $4.0 million - $12.0 million to $9.0 million - $13.0 millionZYNRELEF® unit demand grew 6.3% in Q2 2025 as compared to Q1 2025, with revenue impacted by a temporary wholesaler adjustment from the 400mg VAN transition; momentum building ahead of expanded commercial initiatives and dedicated sales team in Q3 2025APONVIE® unit demand grew 19% in Q2 2025 as compared to Q1 2025, supported by increased adoption in hospital sys

    8/8/25 7:45:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Heron Therapeutics Inc.

    SC 13G - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

    11/12/24 9:32:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Heron Therapeutics Inc. (Amendment)

    SC 13D/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

    5/31/24 11:08:56 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Heron Therapeutics Inc. (Amendment)

    SC 13G/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

    2/14/24 4:37:34 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care